Ownership history in WASATCH ADVISORS LP · 51 quarters on record
This page tracks every 13F SEC filing in which WASATCH ADVISORS LP reported a position in Esperion Therapeutics Inc. (ESPR). Data includes quarterly share count, position size as % of portfolio, estimated market value, and end-of-quarter stock price — sourced directly from SEC EDGAR 13F filings.
| Quarter | Action | Shares | Change | Chg % | % of Fund | Mkt Value | Price (EOQ) |
|---|---|---|---|---|---|---|---|
| 2025 Q4 | ADDED | 9,445,759 | +2,383,902 | +33.8% | 0.21% | $34.9M | $3.70 |
| 2025 Q3 | REDUCED | 7,061,857 | -3,278,404 | -31.7% | 0.10% | $18.7M | $2.65 |
| 2025 Q2 | REDUCED | 10,340,261 | -590,996 | -5.4% | 0.05% | $10.2M | $0.98 |
| 2025 Q1 | REDUCED | 10,931,257 | -13,551,001 | -55.4% | 0.09% | $15.7M | $1.44 |
| 2024 Q4 | ADDED | 24,482,258 | +1,136,245 | +4.9% | 0.27% | $53.9M | $2.20 |
| 2024 Q3 | ADDED | 23,346,013 | +6,483,070 | +38.4% | 0.19% | $38.5M | $1.65 |
| 2024 Q2 | ADDED | 16,862,943 | +7,733,296 | +84.7% | 0.20% | $37.4M | $2.22 |
| 2024 Q1 | ADDED | 9,129,647 | +238,544 | +2.7% | 0.13% | $24.5M | $2.68 |
| 2023 Q4 | REDUCED | 8,891,103 | -2,634,997 | -22.9% | 0.15% | $26.6M | $2.99 |
| 2023 Q3 | REDUCED | 11,526,100 | -1,613,456 | -12.3% | 0.07% | $11.3M | $0.98 |
As of 2025 Q4 — sorted by position size